Prothena Corporation plc (PRTA) and BeiGene Ltd. (NASDAQ:BGNE) Contrasting side by side

As Biotechnology companies, Prothena Corporation plc (NASDAQ:PRTA) and BeiGene Ltd. (NASDAQ:BGNE) are our subject to compare. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prothena Corporation plc N/A 494.47 180.94M -4.63 0.00
BeiGene Ltd. 174.03M 45.23 507.77M -9.61 0.00

In table 1 we can see Prothena Corporation plc and BeiGene Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows Prothena Corporation plc and BeiGene Ltd.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Prothena Corporation plc 0.00% -47.9% -33%
BeiGene Ltd. -291.77% -38.8% -29.6%

Liquidity

The current Quick Ratio of Prothena Corporation plc is 19.3 while its Current Ratio is 19.3. Meanwhile, BeiGene Ltd. has a Current Ratio of 11.6 while its Quick Ratio is 11.5. Prothena Corporation plc is better positioned to pay off its short-term and long-term debts than BeiGene Ltd.

Institutional and Insider Ownership

Roughly 0% of Prothena Corporation plc shares are owned by institutional investors while 77.8% of BeiGene Ltd. are owned by institutional investors. Prothena Corporation plc’s share owned by insiders are 90.1%. On the other hand, insiders owned about 0.1% of BeiGene Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Prothena Corporation plc -3.66% -11.14% -17.36% -17.48% -71.5% -69.14%
BeiGene Ltd. -11.06% 10.42% -17.53% -31.81% 41.72% 39.54%

For the past year Prothena Corporation plc had bearish trend while BeiGene Ltd. had bullish trend.

Summary

On 5 of the 9 factors Prothena Corporation plc beats BeiGene Ltd.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to develop and commercialize BeiGene, Ltd.Â’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317. BeiGene, Ltd. was founded in 2010 and is based in Camana Bay, Cayman Islands.